Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda(Iwate Medical University), Yasuhiro Takikawa(Iwate Medical University), Nobukazu Tanabe(Sendai Medical Center), Wataru Sato(Akita University), Kazumichi Abe(Fukushima Medical University), Katsunori Iijima(Akita University), Go Igarashi(Hirosaki University), Hiromasa Ohira(Fukushima Medical University), Kazuo Okumoto(Yamagata University), Masashi Fujita(Institute of Neuroimmunology of the Slovak Academy of Sciences), Masashi Ninomiya(Tohoku University), Shinsaku Fukuda, Tomohiro Katsumi(Mayo Clinic), Yoshiyuki Ueno(Yamagata Prefectural University of Health Sciences), Chikara Iino(Hirosaki University), Tetsu Endo(Hirosaki University), Takayoshi Oikawa(Iwate Medical University), Atsushi Masamune(Tohoku University), Hiroshi Numao(Aomori Prefectural Central Hospital)
Cited by 45
Related Papers
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
|Cancer Research|2019|328
Variants in CPA1 are strongly associated with early onset chronic pancreatitis
|Nature Genetics|2013|305
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272